BlackRock Inc. lifted its stake in shares of Glaukos Corp (NYSE:GKOS) by 6.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,957,114 shares of the medical instruments supplier’s stock after purchasing an additional 119,811 shares during the quarter. BlackRock Inc. owned about 5.66% of Glaukos worth $50,200,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Wasatch Advisors Inc. bought a new position in Glaukos in the 4th quarter valued at about $661,000. Peregrine Capital Management LLC lifted its position in Glaukos by 32.6% in the 4th quarter. Peregrine Capital Management LLC now owns 622,144 shares of the medical instruments supplier’s stock valued at $15,958,000 after acquiring an additional 152,990 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Glaukos by 93.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 142,655 shares of the medical instruments supplier’s stock valued at $4,708,000 after acquiring an additional 69,018 shares in the last quarter. Taylor Frigon Capital Management LLC bought a new position in Glaukos in the 4th quarter valued at about $1,543,000. Finally, New York State Common Retirement Fund lifted its position in Glaukos by 24.9% in the 3rd quarter. New York State Common Retirement Fund now owns 141,923 shares of the medical instruments supplier’s stock valued at $4,683,000 after acquiring an additional 28,330 shares in the last quarter.
Glaukos stock opened at $31.38 on Friday. Glaukos Corp has a 52 week low of $23.08 and a 52 week high of $51.51. The company has a market cap of $1,115.88, a price-to-earnings ratio of 214.13 and a beta of 1.05.
In other news, Director Orbimed Advisors Llc sold 836,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $32.02, for a total transaction of $26,784,730.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jonathan Silverstein sold 464,583 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $32.29, for a total transaction of $15,001,385.07. The disclosure for this sale can be found here. 16.40% of the stock is owned by company insiders.
Several brokerages recently weighed in on GKOS. Cantor Fitzgerald set a $48.00 price target on shares of Glaukos and gave the company a “buy” rating in a research report on Wednesday, January 10th. Zacks Investment Research cut shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 13th. BMO Capital Markets reaffirmed a “buy” rating on shares of Glaukos in a research report on Monday, December 11th. ValuEngine cut shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Finally, William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. Glaukos has an average rating of “Buy” and a consensus price target of $41.25.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3337174/glaukos-corp-gkos-shares-bought-by-blackrock-inc.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.